Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements research uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availab... https://vernonz795csv1.tusblogos.com/profile